NEW YORK – Novartis said on Tuesday that its investigational targeted radioligand therapy 177Lu-PSMA-617 has demonstrated a significant survival benefit as a treatment for prostate-specific membrane-antigen (PSMA)-positive, metastatic castration-resistant prostate cancer (mCRPC), and that the company plans to file for regulatory approval for the treatment in the US and EU this year.